1.. INTRODUCTION
================

In the treatment of Multiple Sclerosis (MS) we can distinguish: the treatment of relapse, treatment for slowing the progression of disease and symptomatic treatment. Interferons belong to the category of treatment that is slowing the progression of the disease or in a group of immunomodulators ([@R1], [@R2], [@R3]). These are a group of proteins that normally produce cells in response to viral infection and other incentives. It was first described in 1957 and was named for its ability to interfere (clash) with the viruses. The U.S. Food and Drug Administration (FDA) has approved three forms of interferon beta for treating MS. Beta interferon (IFN-B) has multiple effects on the immune system, including an increase in suppressor cell activity and stopping antigens that stimulate other immune cells ([@R4]). Activity of beta-interferon has a network effect in reducing the immune response that is directed against myelin in the central nervous system in people with MS ([@R5]). Destruction of myelin (demyelination) causes a slowing of nerve impulses, or stops them and produces the symptoms of MS. Beta interferon reduces the number of relapses in patients with relapsing--remitting form of MS-E ([@R6]). The original concept of providing two years of interferon was abandoned, and in today's guide to good practice in the treatment of multiple sclerosis recommended long-term use of interferon with the monitoring of therapeutic efficacy and occurrence of neutralizing antibodies. Interferon beta: reduced number and intensity of relapses, slow the progression of physical disability, reduce the number of active lesions (plaques) on MRI, reducing the need for steroids, and reduces the number of days spent in hospital ([@R7]).

Interferon β-1b in a dose of 8 MIU subcutaneously every other day is the therapy that was applied in patients with RR, which in the past two years have had at least two relapses. The most common side effects of interferon: The reaction at the injection site--swelling, redness, discomfort, "flu-like" symptoms--fever, chills and shivering. Symptoms usually disappear after the first couple weeks of treatment ([@R8]).

FDA in 1996 approved a slightly different form of interferon beta, interferon beta-1a, which is derived from mammalian cells using recombined DNA technology with market name Avonex. To be taken once a week by injection into a muscle. During 1997 Swiss pharmaceutical company, Ares-Serono announced positive results of international clinical trials Rebif and other forms of interferon beta-1a. Rebif is administered by subcutaneous injection three times a week ([@R9]).

Treatment with interferon beta-1b (Betaferon) should be initiated under the supervision of a physician, prior to preparing the solution for injection from the contents of the vial with 1.2 ml of solvent, and then l.0 ml of solution (8.0 MIU) injected subcutaneously every other day. To reduce the risk of necrosis at the injection site aseptic techniques should be used and change the injection site every day. Interferon beta-lb should be kept in a cool place (2-8 °C) before preparing injection solution is stored in the refrigerator where it can be kept for 3 hours. When the patient's course of treatment determine the direction of the nomination for the application of interferon therapy, it is necessary to conduct a comprehensive analysis of all factors affecting the determination, when it comes to determining the type of interferon therapy that will be used in patients with MS, and relationship to other medications used to treat MS.

The goal of this study was to analyze the patients with multiple sclerosis who have passed the commission for multiple sclerosis at the Neurological Clinic, Clinical Center University of Sarajevo (CCUS) for a referral to the Commission for multiple sclerosis by Federal Ministry of Health in 2009 by the total number of examined, gender differences, diagnostic tests (MRI, CSF, EP), EDSS, and give the review of the subgroup that received interferon through the Federal Solidarity Fund in terms of the difference between the groups which is recommended interferon and the subgroup that had received it.

2.. MATERIAL AND METHODS
========================

In this retrospective, uncontrolled, non randomized study data was taken from medical records of patients at the Neurological Clinic CCUS. In the study participated 34 patients who passed commission of which 16 patients received interferon therapy.

The material for our work was the histories of patients who are registered as patients who were examined by a Commission for multiple sclerosis at the Neurological Clinic CCUS in 2009. For each patient was filled a specially designed questionnaire established by our neighbors.

3.. RESULTS
===========

Results are presented at Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}, Table [5](#T5){ref-type="table"}, Table [6](#T6){ref-type="table"}, Table [7](#T7){ref-type="table"}, Table [8](#T8){ref-type="table"}, Table [9](#T9){ref-type="table"}, [10](#T10){ref-type="table"} and Figure [1](#F1){ref-type="fig"}, Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"} and Figure [4](#F4){ref-type="fig"}.

Gender structure
----------------

During the monitoring period 34 patients received recommendations for therapy with interferon. As for the gender differences from the 34 patients 25 were women and 9 men.

4.. DISCUSSION
==============

In our study there were 34 patients, with statistically sibilantly more women.

According to literature data, the ratio of women to men in patients with multiple sclerosis ranges from 2.03:1 to 3.1:1. Van Bockstael in 2004 listed prevalence for women 96.3/100000 inhabitants, for males 41.9/100000 inhabitants in France as the comparative results from our research ([@R10]). Hooshmand reported the ratio of women versus men 2.03:1 for patients in Iran ([@R11]). Ratio of 3:1 in our material is analogous to data from epidemiological studies of disease distribution between the sexes in the middle risks countries ([@R12]). Index of patients and epidemiological studies in our country does not yet exist. There are data for individual clinical centers as a tertiary level of health care where they diagnose and treat multiple sclerosis. The most used diagnostic criteria used by a range of age 10-59 years when the disease occurs, in contrast to earlier studies that used upper limit of the age of 50 years. However, cases of illness are clearly described in childhood and old age. Duquette has found that 2.7% of cases of the disease in its center began before 16 years of age and for these younger cases was higher proportion of women/men (3:1) ([@R13]). The clinical material of Neurology Clinic CCUS for fifteen years showed the youngest patient was 15, and the oldest 54 years ([@R14]). Between January 1^st^ 2005 and June 30^th^ 2005 Alajbegovic and associates treated at Neurology Clinic in Sarajevo 21 patients with a secure multiple sclerosis (16 women and 5 men), average age 33 years. The youngest patient was 21 years old and the oldest 52 years ([@R16]).

The mean age of our patients was 34 years with a SD of 7 years. We can say that the patients in our study had a mean age comparative to the results from the literature. So Sepcic stated that he average life age for disease onset is 25.1 years. It should be noted that an early start according to the majority of authors correlate with the benign course of disease. Beginning after the 36 years of age is considered a negative factor for prognosis in terms of flow and progression ([@R16], [@R17]).

No statistically significant differences was found in relation to gender, age and diagnostic tests in the group of patients who were examined by the Commission and have been waiting for the interferon therapy and patients who received interferon therapy for a time period of our research. This can be simply explained by the fact that multiple sclerosis is a disease of time and space, and that all patients have already passed the Commission for interferon therapy, and that the difference was actually in a time when they will begin interferon therapy, since the funds from the Federal Fund which finance interferon therapy are limited. All patients who did not receive interferon therapy were placed on a waiting list. Please note that the EDSS of patients who were waiting for interferon was statistically insignificantly higher as a logical result given that one of the parameters of the ranking list and at the same place at the Commission for multiple sclerosis by the Federal Ministry of Health was EDSS score and age.

If we take this information then we can safely say that we have started to treat our patients during 2009 at an optimal age.

Committee for multiple sclerosis at the Federal Ministry of Health at its first session in 2005 set the criteria for the treatment of multiple sclerosis with interferon. The criteria are connected to guidelines for the treatment of multiple sclerosis by American and European groups for the treatment of patients.

The criteria were: age of 18-55 years, certainly the diagnosis of multiple sclerosis, the absence of mental disorders, the absence of pregnancy and the EDSS score.

Within the diagnostic criteria finding of intrathecal synthesis of immunoglobulins, IgG is a crucial test. Proteins in cerebrospinal fluid were positive in 47% of our respondents. For other subjects we do not have data on the findings of the lumbar puncture. This explains the fact that some of the patients were previously hospitalized or diagnostic relevant tests were done in other centers.

Timely diagnosis of multiple sclerosis has many direct benefits for the patients: to remove the uncertainty of diagnosis, to identify candidates for therapy, provides guidelines for disease modifying therapy and significantly improve quality of patient's life.

MRI and CSF are key laboratory tests, their sensitivity increases over time.

All other laboratory tests are additional. Para clinical tests included MRI, CSF (cerebrospinal fluid) and visually evoked potential (VEP). CSF parameters include a recommendation to use more sensitive methods to determine oligoclonal ribbons and demonstrate intrathecal IgG immunoglobulins synthesis ([@R18]).

All our patients had definitely been diagnosed with multiple sclerosis.

Average EDSS score for men was 1.8056, for women 1.9, and a total EDSS score of 1.875. EDSS score was used to monitor disease progression and monitoring the effects of therapies to stop disease progression, which means that patients treated with immunomodulators had lower score and level of disability.

The first prospective, multicenter, randomized study to compare the results of the effectiveness of interferon beta-1b (8MIU) every other day subcuteously and interferon beta-1a (6 MIU) once a week was the INCOMIN study ([@R19]) ([@R19]).

Criteria for inclusion implied RRMS patients with a Kurtzke EDSS score of 1-3.5, with two or more exacerbations in the past two years. Study included 188 patients aged 18-50 years. Our EDSS findings are comparable to the results of this study.

The first controlled study that demonstrated the effectiveness of systemically administered interferon beta has started in 1988, which was double-blind, placebocontrolled, included patients with RRMS with EDSS 0-5.5, and with at least two exacerbations in the previous two years. Included were 372 patients, divided into three groups, one receiving placebo, the other 1.6 MIU of interferon beta-lb, and the third 8.0 MIU of interferon beta-lb, subcutaneously every other day (IFNB Multiple Sclerosis Study Group, 1993) ([@R20]).

The results of this study after two years showed that patients who received interferon beta in dose of 8.0 MIU had significant reduction, for almost 1/3 in the annual exacerbation number in comparison with the placebo group. The median time to occurrence of the first exacerbation was significantly prolonged, about two times longer than in the group that received 8 MIU compared to the placebo group. Significantly was reduced the number of hospital days and the need for administration of steroids.

Significantly delayed exacerbations time in people with RRMS 2 and 3 years after starting the treatment with Betaferon, was more pronounced in those who received 8 MIU of interferon β-1b ([@R21]).

Currently in the world are in progress more than 50 studies in the 2^nd^ or 3^rd^ phase clinical trials with different drugs for the treatment of patients suffering from multiple sclerosis.

In the guides for MS therapy still the first line of choice are interferons in the onset of illness.

Since 2005 at the expense of the Federal Solidarity Fund were treated 117 patients. In the Federation of Bosnia and Herzegovina, we can say that the percentage of patients who are optimally treated is less than 10%. The fact is that the diagnostic tests in the context of the world's barometer of treatment of patients with multiple sclerosis. Hopefully those therapeutic guidelines will go in this direction ([@R21]).

5.. CONCLUSION
==============

For the period of year 2009 a total of 34 patients were examined with multiple sclerosis who received a recommendation for therapy with interferon sponsored by the Federal Solidarity Fund at the Neurology Clinic CCUS as one of the clinics for recommendation of immunomodulatory therapy.

In the sample there were significantly more female patients. There was no statistically significant difference in the EDSS score between male and female patients. We did not find statistically significant difference in the findings of MRI, CSF and evoked potentials between male and female patients.

Diagnostic criteria for multiple sclerosis were met by all candidates for interferon therapy.

The average EDSS score was 1.8.

From the total number of 34 patients who were examined by the commission 16 patients received interferon therapy, others were placed on the waiting list.

There were no significant differences in distribution between the sexes, age, diagnostic parameters, neurological symptomatology and neurological syndromes among patients who received interferon, and patients who were waiting for treatment.

The treatment of patients with interferon in our study shows that 47% of patients who were examined by the Commission received interferon therapy in a timely manner, or in early stage disease when immunomodulators should be given and when they are most effective. We believe that a greater pressure is needed on health insurance funds in order that patients suffering from multiple sclerosis start treatment with immunomodulators time, delayed the progression of the disease, significantly improve the quality of life and make it a longer period of productive life and social functioning, so in essence put less burden on health funds insurance.
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